Breast cancer stem cells were firstly discovered by Al-Hajj et al. (2003) . Many scientists interested in targeting them as an important solution to "remove" the root of breast cancer. However, more and more publications showed that breast cancer stem cells are the heterogenous population that expression of some markers can be different between them. Particularly, some different markers were considered as markers of breast cancer stem cells. Therefore, what are gold standards of these cells? In this publication, we discussed some conflicts about markers of breast cancer stem cells and suggested some gold standards for breast cancer stem cells. 
confirmed by several other studies (Cho, et al., 2008 , Liang, et al., 2013 , Pece, et al., 2010 , Pham, et al., 2011 Where are breast CSCs from?
Breast Increased risk of breast cancer in children exposed to radiationindicates that breast cancer may develop directly from long-lived stem or progenitor cells present in the mammary glands (Miller, et al., 1989 , Modan, et al., 1989 . Importantly, luminal progenitor cells are known to induce the formation of BRCA1-driven tumors (Lim, et al., 2009 , Molyneux, et al., 2010 , Proia, et al., 2011 Based on this result, Atkinson et al. (2013) proposed that CSCs in breast cancer originated from mutated mammary stem cells present in the normal breast tissue (Atkinson, et al., 2013 (Gupta, et al., 2011 , Meyer, et al., 2009 , Piggott, et al., 2011 .
Interconversion of CSCs in breast cancer cell lines was clearly recorded by Gupta et al. (2011 (Meyer, Fleming, Ali, Pesesky, Ginsburg and Vonderhaar, 2009 ). These evidences confirmed that breast non-CSCs could be automatically converted into
CSCs both in vitro and in vivo (Fig. 1 ).
Some recent studies have shown that actively transdifferentiated breast non-CSCs can be converted into CSCs after treatment with some defined factors. CSC-like cells were produced after the transfection of MCF10Acells with SRC oncogene (Iliopoulos, et al., 2011) . Moreover, the CSC-conditioned medium can convert non-CSCs into CSCs (Iliopoulos, Hirsch, Wang and Struhl, 2011) . Shaffer et al. also produced CSCs by transfecting non-CSCs withSV40andH-ras (Chaffer, et al., 2011) .
Some studies have shown that breast CSCs can (Magni, Shammah et al. 1996) . Due to this property, ALDH1A is known as a contributing factor to chemotherapy resistance of hematopoietic stem cells.
In the recent years, ALDH1A has been thought to be expressed in a sub-population of breast cancer cells (Fig. 2) . These ALDH + breast cancer cells exhibit stem cell properties (Ginestier, Hur et al. 2007 ). Clinically, ALDH + is suggested to be a prognostic marker to predict metastasis 
